---
title: "Topol, at AHA Sessions, Lists Underused Tools in Cardiovascular Care"
description: "Eric Topol, MD, founder and director of Scripps Translational Research Institute and professor of molecular medicine at Scripps Research, told attendees at the American Heart Association Scientific Sessions (Nov. 6-9, 2026, Chicago) that cardiologists are leaving a range of available tools unused. The remarks came in an opening session address, according to Healio; Topol received the AHA's James B. Herrick Award of Outstanding Achievement in Clinical Cardiology at the meeting. The source reports no study data, sample sizes or endpoints — the presentation was a list of practices Topol said are underused, not a trial."
canonical_url: https://clinicalterminal.com/article/107734596
section: cardiology
byline: The Desk · AI-assisted
date_published: 2026-11-09T01:57:40.374Z
date_label: November 9, 2026
image: https://firebasestorage.googleapis.com/v0/b/clinical-ai-design.firebasestorage.app/o/desk-heroes%2F3DJBv4eflr16uG9lAScn%2Fhero_0a031178185b_w1920.jpg?alt=media
source: https://clinicalterminal.com
---

# Topol, at AHA Sessions, Lists Underused Tools in Cardiovascular Care

*[Eric Topol, MD](https://app.clinicalterminal.com/person/107734593), founder and director of [Scripps Translational Research Institute](https://app.clinicalterminal.com/hospital/101820173) and professor of molecular medicine at Scripps Research, told attendees at the American Heart Association Scientific Sessions (Nov. 6-9, 2026, Chicago) that cardiologists are leaving a range of available tools unused. The remarks came in an opening session address, according to Healio; Topol received the AHA's James B. Herrick Award of Outstanding Achievement in Clinical Cardiology at the meeting. The source reports no study data, sample sizes or endpoints — the presentation was a list of practices Topol said are underused, not a trial.*

Among the items he cited were exercise prescriptions, referencing an American College of Cardiology scientific statement released in October; polygenic risk scores, which he said cost $20 to run via a single nucleotide polymorphism array while some companies charge $300; six-lead ECG and handheld ultrasound in routine exams; and information embedded in routine medical images, including chest X-rays, mammograms for breast artery calcification (which he said Maryland requires in mammography readouts) and retinal images. He also pointed to the FDA-approved fat attenuation index score (CaRi-Heart, Caristo Diagnostics) for quantifying coronary inflammation.

Topol disclosed serving on scientific advisory boards for [Abridge](https://app.clinicalterminal.com/company/100013903), [Aevius](https://app.clinicalterminal.com/company/107734594), Danaher, Microsoft and [Mercor](https://app.clinicalterminal.com/company/102448).

**Why it matters:** The talk points to workflow and reimbursement questions — Topol recounted colleagues citing lack of reimbursement for handheld ultrasound — that heart programs would face in adopting the practices he described.

## Sources

- [Healio](https://www.healio.com/news/cardiology/20261107/why-arent-we-using-it-topol-lists-missed-opportunities-in-cv-care)

---
Canonical article: https://clinicalterminal.com/article/107734596  
Entity profiles referenced above resolve to https://app.clinicalterminal.com.
